Biotech Values

[DewDiligence]

Phramasset (VRUS) is holding its first-ever webcast as a public company today after completing an IPO in late April. It’s at 3:40 pm ET from the BofA conference and can be accessed at http://www.pharmasset.com .

VRUS is an interesting company with some serious programs in the antiviral arena including a nucleoside polymerase inhibitor for HBV, Clevudine, that is about to start phase-3. The enterprise value (market cap less net cash) is only about $150M.

If anyone here listens to the webcast, I’d be interested in their feedback.